Related Experiment Videos
Expression and purification of Plasmodium falciparum MSP-1(42): A malaria vaccine candidate
Christian Epp1, Christian W Kauth, Hermann Bujard
1Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), Im Neuenheimer Feld 282, D-69120, Heidelberg, Germany.
Abstract:
The C-terminal 42.10(3) Da portion of the merozoite surface protein (MSP-1) of the human malaria parasite Plasmodium falciparum is of interest, not only because it may constitute an essential part of a future anti-malaria vaccine, but also due to its role during the infection of erythrocytes by the parasite. We have cloned and expressed two synthetic DNA sequences encoding the two prototypic MSP-1(42) variants in E. coli. When over-produced, both proteins form insoluble aggregates which were isolated in high purity and yield. After solubilisation and refolding in vitro, both proteins were purified to homogeneity by a three-step procedure applying Ni-chelate, size exclusion and immuno-affinity chromatography. After purification, both proteins meet key criteria of preparations for clinical use. First, conformational studies suggest proper folding of the proteins, particularly in the region containing two EGF-like domains. Polyclonal serum raised against E. coli produced MSP-1(42) recognizes native MSP-1 in Plasmodium infected erythrocytes as shown by immunofluorescence.
Insights
Researchers developed a pure, properly folded merozoite surface protein (MSP-1) from the malaria parasite Plasmodium falciparum. This protein fragment, MSP-1(42), shows promise for malaria vaccines and understanding parasite infection.
Area of Science:
- Parasitology
- Vaccine Development
- Protein Biochemistry
Background:
- The C-terminal 42.10(3) Da portion of merozoite surface protein 1 (MSP-1) from Plasmodium falciparum is crucial for erythrocyte infection.
- MSP-1(42) is a potential target for anti-malaria vaccines.
Purpose of the Study:
- To clone and express two prototypic MSP-1(42) variants.
- To purify these variants to homogeneity for potential clinical use.
- To assess protein folding and antigenicity.
Main Methods:
- Cloning and expression of synthetic DNA sequences in E. coli.
- Isolation of insoluble protein aggregates.
- In vitro solubilization and refolding.
- Purification using Ni-chelate, size exclusion, and immuno-affinity chromatography.
- Conformational studies and immunofluorescence assays.
Main Results:
- High purity and yield of over-produced MSP-1(42) variants obtained as insoluble aggregates.
- Successful purification to homogeneity after solubilization and refolding.
- Conformational studies indicated proper protein folding, including EGF-like domains.
- Polyclonal serum recognized native MSP-1 in infected erythrocytes.
Conclusions:
- The purified MSP-1(42) variants meet criteria for clinical preparations.
- The study demonstrates the feasibility of producing folded, potentially functional MSP-1(42) for vaccine research.
- The findings support MSP-1(42) as a viable candidate for malaria vaccine development.